Accelerate Your Product to Market with Needle-free Delivery

With PharmaJet’s commercialized products and our technical and clinical expertise, you can progress rapidly from pre-clinical data into successful phase 1, 2 and 3 studies.

80+
Development Partners

 

100+
Studies in Progress

 

65+
Studies Completed

Strategic Alliances with PharmaJet

Many leading pharmaceutical, biotechnology, and academic institutions have formed strategic alliances with PharmaJet to use our needle-free injection systems to enhance the delivery of their injected medicines and vaccines.

Needle-free delivery provides a safe and often, more effective alternative to traditional injection techniques. We have needle-free devices for intradermal (ID), subcutaneous (SC), and intramuscular (IM) delivery in 0.5 ml and 0.1 mL dose volumes. Variable dose devices are in late stages of development.

Next generation pharmaceutical development proven process

Click on image to enlarge

Our Needle-free Injection Systems Effectively Deliver

✓ Low and high viscosity medicines

✓ Proteins and peptides

✓ Specialty drug therapies

✓ Nucleic acid-based vaccines and therapeutics

Tropis (ID) Clinical Pipeline

2 approved products
11 ongoing clinical studies
54 ongoing preclinical studies
Infectious Disease
INFLUENZA

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

Split egg-derived

Ph 1 Ph 2 Ph 3


HPV

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

VLP

Ph 1 Ph 2 Ph 3


COVID-19

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

samRNA

Ph 1 Ph 2 Ph 3

EUA in India


DNA

Ph 1 Ph 2 Ph 3

EUA in India


DNA

Ph 1 Ph 2 Ph 3


DNA

Ph 1 Ph 2 Ph 3


DNA

Ph 1 Ph 2 Ph 3


DNA

Ph 1 Ph 2 Ph 3


VEEV

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


ONCOLOGY
Breast Cancer

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


HPV

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


Lymphoma

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


OTHER APPLICATIONS
Alzheimer's

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


Stratis (IM/SC) Clinical Pipeline

1 approved products
19 ongoing clinical studies
32 ongoing preclinical studies
INFECTIOUS DISEASE
Influenza

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

Split-egg derived

Ph 1 Ph 2 Ph 3

On label for Afluria


HPV

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

VLP

Ph 1 Ph 2 Ph 3


Hantaan

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


COVID-19

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


DNA

Ph 1 Ph 2 Ph 3


DNA

Ph 1 Ph 2 Ph 3


DNA

Ph 1 Ph 2 Ph 3


HIV

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


HPV/HIV

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


VEEV

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


ONCOLOGY
Cervical Cancer

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


DNA

Ph 1 Ph 2 Ph 3


Head and Neck

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA (neoantigen)

Ph 1 Ph 2 Ph 3


Metastic Solid Tumors

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA (neoantigen)

Ph 1 Ph 2 Ph 3


DNA (neoantigen)

Ph 1 Ph 2 Ph 3


Melanoma

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA (gp100 and TRP-2)

Ph 1 Ph 2 Ph 3


DNA (neoantigen)

Ph 1 Ph 2 Ph 3


Merkel Cell Carcinoma

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3

Fast Track


HPV

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


OTHER APPLICATIONS
Bleeding DIsorders

Vaccine

Phase 1 Phase 2 Phase 3

Approval

Partner

DNA

Ph 1 Ph 2 Ph 3


PharmaJet Vaccine Partnerships

We are interested in collaboration opportunities with partners where our technology can enhance the delivery of injectables in areas such as biologics, vaccines, small molecules, and other therapeutic technology platforms.

PharmaJet currently has active collaborations with a wide variety of partners including emerging biotechnology companies, established pharmaceutical companies, Armed Forces/DoD (Department of Defense), Federal Agencies, among others.

Abnova
BARDA, Biomedical Advanced, Research, And Development Authority
Band Therapeutics
Bill & Melinda Gates foundation
BioNet
CureVac the RNA people®
diomics
DiosVax
EpiVax
Evaxion AI-Immunology
Genexine
Immunoimic Therapeutics, Inc.
Invectys cancer immunotherapeutics
Merck, Be Well
Mid-Atlantic BioTherapeutics
nykode therapeutics
Path
Scancell
Seqirus™ A CSL Company
Serum Institute of India LTD.
Takeda
University of Colorado Health, formerly poudre valley health system
USAMRIID, United States Army Medical Research Institute of Infectious Diseases
Zydus Dedicated to life
Menu